MedTrace Logo

P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis

NCT01708603 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1831

Last updated 2020-01-06

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the safety and efficacy of brodalumab at two different doses

Conditions

Interventions

DRUG

210 mg brodalumab

210 mg brodalumab administered SC

DRUG

140 mg brodalumab

140 mg brodalumab administered SC

DRUG

ustekinumab

45 mg or 90 mg ustekinumab administered SC per the labeled dosing regimen.

DRUG

placebo

Placebo administered SC

Sponsors & Collaborators

  • Bausch Health Americas, Inc.

    lead INDUSTRY

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2014-09-30
Completion
2015-10-31

Countries

  • United States
  • Australia
  • Austria
  • Canada
  • Czechia
  • France
  • Hungary
  • Netherlands
  • Poland
  • Portugal
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01708603 on ClinicalTrials.gov